Pay in 4 interest-free payments of $23.75 Learn more
Ships within 48 hours · Estimated delivery Jul 26 - Jul 31
The overexpression of KDM4A/KDM4B in prostate cancer and their association with androgen receptor suggest that KDM4A/KDM4B are potential progression factors for prostate cancer
Pulmonary actions of LY255283
PubMed PMID: 21933026
[Epub ahead of print] PubMed PMID: 27923910
CUDC-907 was used at 0
TWS119 Size:10mg solid The overexpression of KDM4A/KDM4B inTWS 119 is a potent and selective inhibitor of glycogen synthase kinase 3 (IC50 = 30 nM). TWS119 could activate Wnt catenin pathway and up regulate the expression of CD62L in a dose dependent manner, but it decreased the expression of CD107a. Glycogen synthase kinase (GSK) 3, a constitutively active serine threonine kinase, acts as a key regulator of major signaling pathways, including the Wnt, Hedgehog, and Notch pathways. Product information CAS
US$ 40.99
US$ 550.00
US$ 157.00
US$ 190.00
US$ 275.00
US$ 199.00
US$ 170.00
US$ 262.50
US$ 125.00
US$ 61.00